Abstract
More and more very low birth weight (VLBW) infants around the world survive nowadays, with consequently larger numbers of children developing prematurity-related morbidities, especially bronchopulmonary dysplasia (BPD). BPD is a multifactorial disease and its rising incidence in recent years means that general pediatricians are much more likely to encounter a child born extremely preterm, possibly with BPD, in their clinical practice. Short- and long-term sequelae in VLBW patients may affect not only pulmonary function (principally characterized by an obstructive pattern), but also other aspect including the neurological (neurodevelopmental and neuropsychiatric disorders), the sensorial (earing and visual impairment), the cardiological (systemic and pulmonary hypertension, reduced exercise tolerance and ischemic heart disease in adult age), nutritional (feeding difficulties and nutritional deficits), and auxological (extrauterine growth restriction). For the most premature infants at least, a multidisciplinary follow-up is warranted after discharge from the neonatal intensive care unit in order to optimize their respiratory and neurocognitive potential, and prevent respiratory infections, nutritional deficiencies or cardiovascular impairments.
Conclusion: The aim of this review is to summarize the main characteristics of preterm and BPD infants, providing the general pediatrician with practical information regarding these patients’ multidisciplinary complex follow-up. We explore the current evidence on respiratory outcomes and their management that actually does not have a definitive available option. We also discuss the available investigations, treatments, and strategies for prevention and prophylaxis to improve the non-respiratory outcomes and the quality of life for these children and their families, a critical aspect not always considered. This comprehensive approach, added to the increased needs of a VLBW subjects, is obviously related to very high health-related costs that should be beared in mind.
What is Known: • Every day, a general pediatrician is more likely to encounter a former very low birth weight infant. • Very low birth weight and prematurity are frequently related not only with worse respiratory outcomes, but also with neurological, sensorial, cardiovascular, renal, and nutritional issues. | |
What is New: • This review provides to the general pediatrician a comprehensive approach for the follow-up of former premature very low birth weight children, with information to improve the quality of life of this special population. |
Similar content being viewed by others
Explore related subjects
Discover the latest articles, news and stories from top researchers in related subjects.Avoid common mistakes on your manuscript.
Epidemiology of prematurity and bronchopulmonary dysplasia
Preterm birth is a frequent event, happening in about 10% of pregnancies. Although very preterm and extremely preterm births occur less frequently nowadays, every year 1.1% of newborn infants are born at less than 28 weeks of post-menstrual age (PMA), and with a birth weight of less than 1500 g, defined as very low birth weight (VLBW) [1].
Recent advances in neonatal care have enabled more infants to survive extremely preterm birth, giving rise to more children with prematurity-related morbidities like bronchopulmonary dysplasia (BPD). However, efforts to minimize lung injury have not reduced the incidence of BPD [2], so general pediatricians are increasingly likely to encounter preterm-born children with or without BPD in their clinical practice.
BPD is diagnosed most commonly as oxygen need for 28 days after birth and graded with respiratory support at 36 weeks PMA [3,4,5]. Depending on how BPD is defined, it affects from 6 to 57% [6] of preterm infants. The most often-used definitions of BPD [3,4,5] have been developed to help us to classify infants and to predict the long-term respiratory outcomes of BPD subjects [7].
Even VLBW infants not diagnosed with BPD can experience some degree of lung abnormality during childhood and adulthood, suggesting the presence of a chronic lung disease of prematurity. Their poor lung function poses a risk of a chronic obstructive pulmonary disease (COPD)-like phenotype later in life. Hence the growing attention to monitoring lung function and managing respiratory symptoms in VLBW subjects beyond the neonatal period.
Pathogenesis of BPD
BPD is a multifactorial disease [8] thought to develop already in utero as suggested by metabolomics studies on amniotic fluid [9]. This is part of a wider pathogenic picture in which pre- and post-natal factors affect the immature lungs, making them highly vulnerable to inflammation, direct injury, and impaired development, possibly predisposing them to BPD [10]. The noxae involved include intra- and extra-uterine growth restriction, preeclampsia, chorioamnionitis, maternal smoking, hyperoxia, mechanical ventilation, sepsis, hemodynamically significant patent ductus arteriosus (PDA), and microbiota, all factors that can disrupt lung development. Associated with aberrant repair mechanisms, these factors can exacerbate the histopathology of the lung. BPD is characterized by a reduced alveolar surface area available for gas exchange, an altered angiogenesis with possible consequent pulmonary arterial hypertension, and a widening and thickening of the interstitial spaces due to fibrotic repair mechanisms [8]. Reasonably, the extremely vulnerable lung of the smallest preterm is unlikely to reach term equivalent age without any sign of lung disease, even if not classified as BPD, again suggesting the presence of a chronic lung disease of prematurity [11], in which those with BPD are likely to be the more severe group.
Prevention and early treatment of chronic lung disease during the neonatal period
Several interventions have shown potential for acting on the above-mentioned factors and limiting the burden of BPD and respiratory sequelae of prematurity. They include [12] antenatal corticosteroids; early surfactant administration with less invasive techniques; gentle and protective mechanical ventilation (when necessary); targeted oxygen saturations; early caffeine therapy; postnatal infection control; treatment for hemodynamically significant PDA; and adequate enteral nutrition, preferably with human milk.
There are few options for the pharmacological treatment of evolving BPD and BPD during the newborn’s hospital stay. Systemic corticosteroids are among the most studied: they have shown promise in reducing the incidence of BPD, especially when used within the first 8–14 days of life [13]. The risk of side effects, such as worse neurodevelopmental outcomes [14] and higher mortality rates [15], raises questions over their use, however, and there is still no consensus on the best choice of drug, its dosage, and the timing of its administration [16].
Other frequently prescribed drugs are diuretics, like furosemide, chlorothiazide, and spironolactone, which may be started in hospital, then discontinued at home, depending on the infant’s need for oxygen therapy and post-discharge growth [17].
Preclinical and early clinical studies have generated positive results with stem cells [18, 19] and their products (extracellular vesicles) [20], raising the need for early biomarkers of respiratory outcomes to identify patients at high risk and treat them early with these potentially breakthrough therapies [21, 22].
Meanwhile, general pediatricians will see increasing numbers of preterm-born children with chronic lung disease persisting into adult life [10].
To better support this population, general pediatricians and neonatologists need to work together even before patients are discharged from the neonatal intensive care unit (NICU). Pediatricians should meet the infants and their parents already in hospital and plan the patients’ short-term clinical follow-up with the neonatologist. This is especially crucial for the most fragile infants, like those needing oxygen supplementation at home.
Respiratory outcomes and symptoms after the neonatal period
Children born extremely preterm are at higher risk of both short- and long-term respiratory sequelae [23]. Among them, those with BPD stay longer in the NICU, and are sometimes discharged home with oxygen supplementation [24]. Tracheobronchomalacia is another complication of prematurity and BPD, and a risk factor for longer hospital stays and respiratory problems [25]. The affected infants will consequently need closer monitoring at home.
During the first 2 years of life, infants born extremely preterm, with or without BPD, are hospitalized more often than children born at term [26, 27], suggesting that this population frequently has some degree of lung impairment [11]. These infants also have an immature immune system [28], which puts them at higher risk of severe respiratory infections that may require hospitalization and intensive care, especially in presence of BPD-related pulmonary hypertension [29]. The main pathogens involved are respiratory syncytial virus (RSV) and rhinoviruses that can make preterm subjects’ fragile respiratory systems reach the symptomatic threshold more easily. Exposed to repeated infections and respiratory re-exacerbations, the patients’ already impaired lung structure probably worsens, giving rise to frequent coughing and recurrent wheezing episodes. Pre-school and school-aged children with BPD are consequently at higher risk of asthma-like symptoms.
Monitoring lung function in preschoolers born preterm is not an easy task. It entails using non-routine methods like the forced oscillation or interrupter resistance techniques. Such methods have demonstrated reduced expiratory flows in preterm infants regardless of any BPD diagnosis [30], but results are worse in infants known to have BPD [31]. Lung function has also been found to correlate better with respiratory symptoms than severity of BPD [32].
Several children with airway flow limitations (reduced FEV1) in school age do not improve as they grow older [33, 34]. In adulthood, thanks to a catch-up alveolarization through childhood, they might have alveolar dimensions and number comparable with those of healthy 10- to 14-year-olds, despite a significant difference in FEV1 [35]. The dysanaptic concept may explain this “non-parallel” growth in lung size and airway caliber, such that individuals with BPD and term-born controls differ in expiratory flow rates despite similar lung sizes. It is not clear when and how their flow limitations occur and evolve, but several studies show that individuals born significantly preterm do not match their peers’ lung function at 20–25 years of age, and consequently carry a higher risk of early COPD symptoms [10, 36,37,38]. Infants with intra-uterine growth restriction (IUGR), as well as being at increased risk for BPD, have an even worse respiratory function when compared to non-IUGR infants at a mean age of 11 years [39, 40].
Children born very preterm, and those with BPD especially, may have an impaired exercise tolerance that persists in adolescence and adulthood [23]. This could be due to multiple alterations in their cardiorespiratory system, including airway flow limitation, reduced pulmonary vascular capacity, lower peak oxygen consumption and anaerobic threshold, and altered respiratory mechanics [41].
Treatments available beyond the neonatal period
A main concern for general pediatricians is the current lack of treatments for symptoms of chronic lung disease and its re-exacerbations. Drugs for asthma are frequently prescribed to former BPD and preterm subjects, especially inhaled corticosteroids and bronchodilators [42], but this choice is not based on scientific evidence.
The chronic inflammation in BPD subjects [43, 44], and the normal levels of FeNO (a marker of eosinophilic inflammation) in children born preterm suggest that the inflammatory mechanisms in their airways differ from the eosinophilic inflammation of childhood asthma, raising questions over the long-term use of inhaled corticosteroids for BPD patients [45]. Research on the efficacy of these drugs in preterm-born children is still ongoing [46], but there is still no evidence to support their background use [47]. An expert consensus of the European Respiratory Society (ERS) [42] recommended against using inhaled corticosteroids (low certainty of evidence), and stated that their effects should be carefully monitored during a trial period before any long-term treatment.
Spirometry has documented a certain response to bronchodilators in BPD subjects [48], but the clinical significance of this amelioration has yet to be demonstrated. Chronic use of short-acting bronchodilators (salbutamol, fenoterol) is therefore not recommended, given the adverse effects associated with their overuse as a single therapy described in asthmatic patients.
The ERS task force [42] suggests bronchodilators only for specific subgroups of children with BPD: the most severe cases; those with asthma-like symptoms; those repeatedly hospitalized due to respiratory morbidity; and those with exercise intolerance or evidence of reversible airway obstruction.
Summing up, the evidence on chronic and acute therapies for BPD and its re-exacerbations is scarce. Treatments should be adequately tailored to individual patients. In cases of moderate-severe BPD, or frequent re-exacerbations, we recommend follow-up visits with pediatric pulmonologists, who can help general pediatricians assess patients’ respiratory symptoms and monitor the benefits of any therapies, preferably measuring lung function [49].
On the matter of preventive measures, the picture changes completely.
Palivizumab is a monoclonal IgG antibody against the RSV’s protein F. Adopting a monthly administration protocol, it has been demonstrated to reduce (55%) the hospitalizations for severe RSV infections involving preterm-born infants, especially those with BPD. There is still no standardized European guideline on the use of palivizumab, and national guidelines follow cost-effectiveness considerations [50]. In general, prophylaxis should be considered during the RSV season for infants with BPD in their first year of life. In their second year, it is recommended for infants who continue to require respiratory support (chronic corticosteroid and bronchodilators therapy, diuretics or supplemental) during the 6-month before the start of the RSV season [51, 52]. Palivizumab is considered safe and effective, but the need for repeated injections can be a problem. This will be overcomed by a new single-shot monoclonal antibody, Nirsevimab, with a 5 months half-life [53,54,55].
Given the immature and less competent immune system of infants born preterm, their immunization schedules should not be delayed. Vaccinations should be administered at the same chronological age and according to the same schedule as for term-born infants. Exceptions include: the hepatitis B birth dose, which should be deferred until discharge from hospital or one month of age for infants born at < 2000 g from mothers who test negative for the hepatitis B surface antigen; and the rotavirus vaccine, which is contraindicated in preterm-born infants who have had necrotizing enterocolitis [56]. Adverse events such as apnea can occur after immunization with vaccines [57], so the first dose may be administered in hospital, and before discharge whenever possible for high risk subjects [58, 59].
Respiratory follow-up for children born very preterm and those with BPD
Lung imaging
Using lung imaging to monitor the respiratory health of BPD subjects is not currently routine, but high-definition CT or MRI may be useful in cases of particularly severe respiratory symptoms and/or recurrent hospital admissions [42]. Despite the uncertain benefits of imaging and the radiation exposure risks, other diagnoses influencing such patients’ respiratory status need to be ruled out. A field worth exploring concerns lung ultrasound: it has proved valuable in the neonatal period [60], also for predicting BPD [21, 61], and has numerous applications in pediatric age [62, 63], but its use in the post-NICU follow-up subjects has never been explored.
Lung function tests
There is no standard respiratory follow-up schedule for BPD, but a recent US experts’ survey recommended an early pulmonary consultation (1–2 months after discharge from the NICU) for infants with moderate or severe BPD, and at least a one-off specialist assessment for cases of mild disease [49]. Lung function evaluations in preschoolers former preterm could be performed only with non-routinary techniques, like forced oscillation or interrupter resistance techniques, but could be considered in the most severe cases [30,31,32]. Beyond 5 years of age, spirometry is an easy and non-invasive tool, so it is useful in the longitudinal follow-up of school-age children born preterm, especially if with BPD. Response to bronchodilators should be tested as well, and, if positive, pediatric pulmonologists should be consulted on the need for background therapy [64], and to monitor any effects.
Oxygen therapy at home
General pediatricians have a crucial role in managing BPD infants discharged home with oxygen supplementation. The ERS consensus guidelines [42] recommend maintaining an oxygen saturation target of > 90%, but further studies are needed to establish optimal SpO2 targets in BPD infants. Supplementary oxygen at home for children with chronic neonatal lung disease aims to reduce or prevent pulmonary hypertension, contain intermittent desaturations, reduce airway resistance, promote growth and neurodevelopment, and possibly limit the associated risk of sudden unexplained death in infancy. Parents should be instructed on how to monitor and manage oxygen before their child is discharged, and reminded when at home. The use and evaluation of the pulse oximeter that is provided to oxygen dependent subjects could be trivial for a healthcare provider, but difficult and scary for the anxious parents, that can over- or under-estimate the presence of an alarm. Parametric thresholds should consequently be adequately set and their meaning explained to the caregivers. Parents will also need guidance on the gradual weaning of oxygen supplementation when the time comes [65].
Daycare center attendance
Parents of children born preterm will likely ask for their general pediatricians’ advice about attending daycare centers or kindergarten. Despite the limited scientific evidence available, this advice should take into account local experience, the child’s age, the time of year, the parents’ wishes and possibilities. The first winter of very young infants with severe BPD is clearly of greatest concern, but many factors could influence parents’ decisions, and the potential benefit of kindergarten to their child’s social development should not be overlooked [42].
Smoke avoidance and Hygiene
Caring for children born preterm also includes: avoiding second- and third-hand smoking and the related preventable inflammation and oxidative stress of their already-damaged lungs, and to protect their respiratory health [66]; avoiding crowded places, and rooms full of older children; and ensuring adequate hand hygiene of the care-givers [67].
Other areas of intervention
Prematurity affects multiple systems with potentially lifelong consequences [68], Crump et al. have suggested that “preterm birth should be recognized as a chronic condition that requires long-term follow-up” [69]. The European Foundation for the Care of Newborn Infants (EFCNI) has developed standards of care for infants born preterm from birth to school age. They propose a holistic approach, covering respiratory, cardiovascular and neurological aspects, but also promoting healthy habits, mental health and peer relationships [70]. This would optimize numerous outcomes, and particularly the child’s neurocognitive potential, through the early identification of motor, social or cognitive issues and the provision of appropriate rehabilitation.
Neurological outcomes
BPD is independently associated with adverse neurological outcomes at 12 and 24 months of corrected age. On Bayley III assessments, impairments in one or more neural functions relating to adaptability, gross motor, fine motor, language, or social skills are significantly more common in preterm-born children with BPD. Pulmonary hypertension can also have a negative influence on such neurodevelopmental outcomes [71].
Recent brain MRI studies comparing term-born infants with those born preterm and developing BPD showed a delayed brain maturation in the latter [72]. BPD also influenced cerebellar development [72]. Despite this evidence, brain MRI is suggested for VLBW infants at term equivalent age [73], but after discharge is not a routine part of the BPD infant’s follow-up, when other neurological issues are not suspected.
IUGR is a worsening factor also in the neurological development, being associated with both alterations in brain growth on MRI evaluation at term and poorer toddlerhood outcomes. Infants with a previous diagnosis of IUGR present lower cognitive and motor scores at 22 months and a positive Modified-Checklist for Autism (OR 2.12) compared with adequately grown controls [74].
Infants born preterm are also at higher risk of neuropsychiatric disorders during childhood. The “preterm behavioral phenotype” features a higher risk of symptoms and disorders associated with inattention, anxiety and social difficulties, and a markedly greater prevalence of autism spectrum disorders [75], but also psychosis in adult age [76]. General pediatricians suspecting such issues should refer patients for specialist assessment at an early stage.
Finally, preterm-born infants with severe brain lesions such as stage 3 or 4 intraventricular hemorrhage, periventricular leukomalacia or a history of altered findings on electroencephalography (EEG) should be monitored with serial EEG because they are at higher risk of developing epilepsy [77].
Feeding difficulties
Premature and BPD infants may experience feeding problems, and swallowing dysfunctions that can affect their growth and respiratory function. BPD infants may have tachypnea or low oxygen saturation episodes during breastfeeding due to a poor coordination of sucking and swallowing, and gastroesophageal reflux is common [78]. Little is known about suitable nutritional interventions [79]. Human milk is the best choice also for this population, with the possibility of caloric and proteic supplementation. If a human milk fortifier is used for this purpose, it could be continued up to a corrected age of 56 weeks [80]. When human milk or breastfeeding is not enough to cover the baby’s request, a post-discharge formula rich in calories (72 kcal/100 ml) or a preterm formula (80 kcal/100 ml) may be continued in VLBW infants with extrauterine growth restriction.
Feeding problems, diuretics, postnatal steroids, and an inadequate intake of minerals may impair optimal growth in the first years of life, with consequent deficiencies (such as low iron levels or metabolic bone disease) in preterm infants [81]. So, supplementing vitamins and other elements is mandatory for preterm infants.
Vitamin D contributes to bone mineralization and neuromuscular function, and can also have an anti-inflammatory function [82]. The European Society for Pediatric Gastroenterology, Hepatology and Nutrition suggests a dose of 800–1000 IU/day till full-term then 400 IU, whether the premature infants are fed mother’s milk or formula [83]. Iron is essential for neurodevelopmental outcomes of VLBW infants. Supplementation with a 2–3 mg/kg oral dose of iron is recommended at least until 6–12 months old, depending on the introduction of complementary feeding. A recent meta-analysis on enteral calcium or phosphorus supplementation in preterm-born infants found insufficient evidence of any improvement in the children’s growth and bone health [84]. General pediatricians should assess feeding and nutrition regularly, taking anthropometric measurements and asking parents about any respiratory or digestive problems. A pediatric gastroenterologist and should follow-up infants with gastrointestinal problems requiring the use of a nasogastric tube or a transcutaneous gastrostomy and a nutritionist/dietician could help improve caloric intake.
Auxological parameters
Most VLBW infants are discharged home without an optimal growth during their hospital stay, when the targeted caloric intake is not always achievable [85]. The resulting extrauterine growth restriction means that infants’ auxological parameters are often below the 10th centile at the time of their discharge, but they tend to catch up afterwards. They usually reach adequate growth parameters over the first two years (but can sometimes take 5–6 years) [86], and a better growth seems related to a better neurodevelopment [87].
Cardiovascular and nephrological outcomes
Cardiovascular problems associated with prematurity, such as pulmonary hypertension, need monitoring with echocardiography and specialist cardiologist consultations. Young adults born preterm are also at higher risk of non-communicable diseases [88] like ischemic heart disease [89], hypertension [90], high fasting glucose and total cholesterol levels [91]. It is therefore wise to check premature-born children’s arterial blood pressure during visits to the general pediatrician, and to schedule echocardiography for selected high risk preterm infants, when they reach school age. Multiple earlier assessments are recommended for those still on supplemental oxygen therapy or with abnormal findings at the time of discharge from hospital [64]. Again IUGR subjects seem at higher risk for cardiovascular morbidity and mortality, not only as a consequence of the metabolic diseases, but for the evidenced alterations of cardiac and vasculature structure and function [92].
The numerous aspects of metabolic syndrome (insulin resistance, obesity, and dyslipidemia) should be clinically monitored too, especially in VLBW infants with a history of IUGR, which are at higher risk [93], and it is important to highlight this risk when pediatricians hand over their patients to general practitioners. In fact, individuals born very preterm are also at greater risk of chronic kidney disease (as 60% of nephrons develop in the last trimester of pregnancy) from childhood into mid-adulthood [94], and this adds to their risk of systemic hypertensive disease.
Physical activity
Assessing children’s physical activity levels should be part of the general pediatrician’s routine, especially for children born preterm. Physical activity is recommended in this population, given its known benefits [95], which could positively influence some cardiovascular and metabolic aspects. One study found that even a short (4-week) exercise program could significantly improve the results of the 6-min walking test, incremental shuttle walk test, modified sit and reach test and spirometry in 5-year-olds born preterm [96]. In another study, significant differences in some baseline cardiac MRI parameters between adults born preterm and term-born controls disappeared after the attendance of 14 weeks of thrice-weekly supervised aerobic exercise and resistance training [97].
Audiological and ophthalmological assessments
It is strongly advisable to test preterm-born infants’ sensory functions because their early exposure to numerous drugs (especially antibiotics and loop diuretics) can cause hearing impairment. To identify and treat this issue early on, screening is usually done before discharge, but a follow-up visit should be scheduled a few months later to check infants’ hearing function and ensure any necessary action is taken before they are 6 months old [98].
Visual function should be monitored too, as preterm infants are more likely to have a reduced visual acuity, strabismus, abnormal stereopsis and refractive errors, but routine screening may not detect other problems, such as reduced visual fields, impaired contrast sensitivity, or deficits in cortical visual processing, that may occur in this population [99]. All these issues can interfere with the optimal development of infants born preterm, and their prompt identification and treatment can help to ameliorate the children’s quality of life.
Family care
A final aspect that should be beared in mind concerns the preterm infants’ families. The birth of an extremely premature child dramatically upsets the balance of any couple and family. Then the infant’s discharge from hospital brings new disruptions, imposes new daily routines, adds to parents’ stress and anxiety, leaves them less time for their other children, and so on [100]. Identifying early red flags of parents’ difficulties or mental health issues can be crucial to the future of the whole family and to the infant’s development. Collaborating with national and international foundations like the EFCNI is extremely important to improving the long-term health and quality of life for preterm infants and their families [70].
The “intensive care” team for the discharged VLBW subject
A comprehensive approach to the VLBW subject is consequently strongly recommended and will imply a large multi-specialistic team, coordinated by the general pediatrician and the neonatologist, but including pneumologists, cardiologists, neurologists, neuropsychiatrists, nutritionists, gastroenterologists, nephrologists, endocrinologists, radiologists, ophthalmologists, audiologists and speech, deglutition, and physical therapists. This should also include non-medical figures like support teachers, psychologists and social workers. The access to this panoply of services is not always easy and families could benefit from the support of patients’ associations that can help subjects and their families address the high demand for care and health needs associated with very preterm birth. Patients’ associations have also the important role of patients’ advocacy, speaking out their best interests and highlighting to every involved figure the importance of their role. One of these associations, the European Foundation for the Care of Newborn Infants (EFCNI), has fully accepted this responsibility, and recently published a comprehensive guideline (shared with numerous neonatal medical societies) for the care of all the facets of the newborn infant, especially if preterm born [70].
Health-related costs for VLBW infants’ care
As can be deduced, a preterm born infant requiring a prolonged hospitalization with intensive care needs, implies quite high health-related costs. However, the first hospitalization is only the beginning of an expensive journey, requiring a significantly higher expenditure compared with the neonatal admission of a term born infant, as shown by many different papers on this topic showing similar results even if in different realities [101,102,103], with a particularly high cost when BPD is present [104]. The needs of VLBW infants obviously don’t end with the first hospitalization, but require many specialistic evaluations, medical and physical therapy, cognitive support and so on, implying increased health-related costs possibly through all their life [105], especially for those subjects with BPD [106]. A comprehensive approach to support all the possible critical aspects of the former VLBW subject, would probably imply a high expense at first, but could end in a better quality of life and possibly a lower level of needs subsequently. This aspect surely justifies the important initial disbursement, targeting the best potentiality of each VLBW infant.
To sum up, Table 1 lists the main follow-up assessments and interventions that general pediatricians should consider for former preterm patients, especially those with BPD.
Conclusions
VLBW infants with and without BPD warrant a long-term medical care that still has many aspects that remain unclear. After these infants’ discharge from the NICU, collaboration between the neonatologist and the general pediatrician is fundamental to the child’s proper follow-up and the discontinuation of previously-used therapies. Our increasing understanding of the main problems of children born very preterm suggests the need for a multispecialist follow-up into adulthood, especially for those with severe BPD [64] (Fig. 1). From pre-school age onwards, general pediatricians become the reference figure for preterm-born infants and their parents, so they need to be aware of the options available for improving the quality of life of this population.
References
European Perinatal Health Report (2015) Euro-Peristat. https://www.europeristat.com/index.php/reports/european-perinatal-health-report-2015.html. Accessed 3 Oct 2022
Stoll BJ, Hansen NI, Bell EF et al (2015) Trends in care practices, morbidity, and mortality of extremely preterm Neonates, 1993–2012. JAMA - J Am Med Assoc 314(10):1039–1051. https://doi.org/10.1001/jama.2015.10244
Jobe AH, Bancalari E (2001) Bronchopulmonary dysplasia. In: American Journal of Respiratory and Critical Care Medicine. American Thoracic Society New York, NY. 163:1723–1729. https://doi.org/10.1164/ajrccm.163.7.2011060
Higgins RD, Jobe AH, Koso-Thomas M et al (2018) bronchopulmonary dysplasia: executive summary of a workshop. J Pediatr 197:300–308. https://doi.org/10.1016/j.jpeds.2018.01.043
Jensen EA, Dysart K, Gantz MG et al (2019) The diagnosis of bronchopulmonary dysplasia in very preterm infants an evidence-based approach. Am J Respir Crit Care Med 200(6):751–759. https://doi.org/10.1164/rccm.201812-2348OC
Hines D, Modi N, Lee SK et al (2017) Scoping review shows wide variation in the definitions of bronchopulmonary dysplasia in preterm infants and calls for a consensus. Acta Paediatr 106(3):366–374. https://doi.org/10.1111/APA.13672
Bancalari E, Jain D (2018) Bronchopulmonary dysplasia: can we agree on a definition? Am J Perinatol 35(6):537–540. https://doi.org/10.1055/s-0038-1637761
Bonadies L, Zaramella P, Porzionato A, Perilongo G, Muraca M, Baraldi E (2020) Present and future of bronchopulmonary dysplasia. J Clin Med 9(5):1539. https://doi.org/10.3390/jcm9051539
Baraldi E, Giordano G, Stocchero M et al (2016) Untargeted metabolomic analysis of amniotic fluid in the prediction of preterm delivery and bronchopulmonary dysplasia. Motta A, ed. PLoS One 11(10):e0164211. https://doi.org/10.1371/journal.pone.0164211
Baraldi E, Filippone M (2007) Chronic lung disease after premature Birth. N Engl J Med 357(19):1946–1955. https://doi.org/10.1056/NEJMra067279
Jobe AH, Bancalari E (2021) An all-inclusive perspective on bronchopulmonary dysplasia. J Pediatr 234:257–259. https://doi.org/10.1016/j.jpeds.2021.03.063
Aschner JL, Bancalari EH, McEvoy CT (2017) Can we prevent bronchopulmonary dysplasia? J Pediatr 189:26. https://doi.org/10.1016/J.JPEDS.2017.08.005
Ramaswamy VV, Bandyopadhyay T, Nanda D et al (2021) Assessment of postnatal corticosteroids for the prevention of bronchopulmonary dysplasia in preterm neonates: a systematic review and network meta-analysis. JAMA Pediatr Published online. https://doi.org/10.1001/jamapediatrics.2020.6826
Filippone M, Nardo D, Bonadies L, Salvadori S, Baraldi E (2019) Update on postnatal corticosteroids to prevent or treat bronchopulmonary dysplasia. Am J Perinatol 36(S02):S58–S62. https://doi.org/10.1055/s-0039-1691802
Bassler D, Shinwell ES, Hallman M et al (2018) Long-term effects of inhaled budesonide for bronchopulmonary dysplasia. N Engl J Med 378(2):148–157. https://doi.org/10.1056/NEJMoa1708831
Doyle LW (2021) Postnatal corticosteroids to prevent or treat bronchopulmonary dysplasia. Neonatology 118(2):244–251. https://doi.org/10.1159/000515950
Bhandari A, Panitch H (2018) An update on the post-NICU discharge management of bronchopulmonary dysplasia. Semin Perinatol 42(7):471–477. https://doi.org/10.1053/J.SEMPERI.2018.09.011
Ahn SY, Chang YS, Lee MH et al (2021) Stem cells for bronchopulmonary dysplasia in preterm infants: A randomized controlled phase II trial. Stem Cells Transl Med 10(8):1129–1137. https://doi.org/10.1002/sctm.20-0330
Powell SB, Silvestri JM (2019) Safety of intratracheal administration of human umbilical cord blood derived mesenchymal stromal cells in extremely low birth weight preterm infants. J Pediatr 0(0). https://doi.org/10.1016/j.jpeds.2019.02.029
Porzionato A, Zaramella P, Dedja A et al (2021) Intratracheal administration of mesenchymal stem cell-derived extracellular vesicles reduces lung injuries in a chronic rat model of bronchopulmonary dysplasia. Am J Physiol Lung Cellular Mole Physiol. https://doi.org/10.1152/ajplung.00148.2020
Pezza L, Alonso-Ojembarrena A, Elsayed Y et al (2021) Meta-analysis of lung ultrasound scores for early prediction of bronchopulmonary dysplasia. Ann Am Thorac Soc. https://doi.org/10.1513/annalsats.202107-822oc
Álvarez-Fuente M, Moreno L, Mitchell JA et al (2019) Preventing bronchopulmonary dysplasia: new tools for an old challenge. Pediatr Res 85(4):432–441. https://doi.org/10.1038/s41390-018-0228-0
Moschino L, Bonadies L, Baraldi E (2021) Lung growth and pulmonary function after prematurity and bronchopulmonary dysplasia. Pediatr Pulmonol. https://doi.org/10.1002/ppul.25380
Priante E, Moschino L, Mardegan V, Manzoni P, Salvadori S, Baraldi E (2016) Respiratory outcome after preterm birth: a long and difficult journey. Am J Perinatol 33(11):1040–1042. https://doi.org/10.1055/s-0036-1586172
Hysinger EB, Friedman NL, Padula MA et al (2017) Tracheobronchomalacia is associated with increased morbidity in bronchopulmonary dysplasia. Ann Am Thorac Soc 14(9):1428–1435. https://doi.org/10.1513/ANNALSATS.201702-178OC
Pramana IA, Latzin P, Schlapbach LJ et al (2011) Respiratory symptoms in preterm infants: Burden of disease in the first year of life. Eur J Med Res 16(5):223–230. https://doi.org/10.1186/2047-783x-16-5-223
Resch B, Kurath-Koller S, Eibisberger M, Zenz W (2016) Prematurity and the burden of influenza and respiratory syncytial virus disease. World J Pediatr 12(1):8–18. https://doi.org/10.1007/S12519-015-0055-X
Martinez FD (2019) Childhood asthma inception and progression: role of microbial exposures, susceptibility to viruses and early allergic sensitization. Immunol Allergy Clin North Am 39(2):141–150. https://doi.org/10.1016/J.IAC.2018.12.001
Lagatta JM, Hysinger EB, Zaniletti I et al (2018) The impact of pulmonary hypertension in preterm infants with severe bronchopulmonary dysplasia through 1 year. J Pediatr. https://doi.org/10.1016/j.jpeds.2018.07.035
Baraldi E, Filippone M, Trevisanuto D, Zanardo V, Zacchello F (1997) Pulmonary function until two years of life in infants with bronchopulmonary dysplasia. Am J Respir Crit Care Med 155(1):149–155. https://doi.org/10.1164/AJRCCM.155.1.9001304
Hoo AF, Gupta A, Lum S et al (2014) Impact of ethnicity and extreme prematurity on infant pulmonary function. Pediatr Pulmonol 49(7):679–687. https://doi.org/10.1002/PPUL.22882
Thunqvist P, Gustafsson P, Norman M, Wickman M, Hallberg J (2015) Lung function at 6 and 18 months after preterm birth in relation to severity of bronchopulmonary dysplasia. Pediatr Pulmonol 50(10):978–986. https://doi.org/10.1002/PPUL.23090
Moschino L, Stocchero M, Filippone M, Carraro S, Baraldi E (2018) Longitudinal assessment of lung function in survivors of bronchopulmonary dysplasia from birth to adulthood the Padova BPD study. Am J Respir Crit Care Med 198(1):134–137. https://doi.org/10.1164/rccm.201712-2599LE
Fortuna M, Carraro S, Temporin E et al (2016) Mid-childhood lung function in a cohort of children with “new bronchopulmonary dysplasia.” Pediatr Pulmonol 51(10):1057–1064. https://doi.org/10.1002/PPUL.23422
Narayanan M, Beardsmore CS, Owers-Bradley J et al (2013) Catch-up alveolarization in ex-preterm children: evidence from 3He magnetic resonance. Am J Respir Crit Care Med 187(10):1104–1109. https://doi.org/10.1164/rccm.201210-1850OC
Simpson SJ, Turkovic L, Wilson AC et al (2018) Lung function trajectories throughout childhood in survivors of very preterm birth: a longitudinal cohort study. Lancet Child Adolesc Health 2(5):350–359. https://doi.org/10.1016/S2352-4642(18)30064-6
Doyle LW, Faber B, Callanan C, Freezer N, Ford GW, Davis NM (2006) Bronchopulmonary dysplasia in very low birth weight subjects and lung function in late adolescence. Pediatrics 118(1):108–113. https://doi.org/10.1542/peds.2005-2522
Vollsæter M, Clemm HH, Satrell E et al (2015) Adult respiratory outcomes of extreme preterm birth a regional cohort study. Ann Am Thorac Soc 12(3):313–322. https://doi.org/10.1513/AnnalsATS.201406-285OC
Ronkainen E, Dunder T, Kaukola T, Marttila R, Hallman M (2016) Intrauterine growth restriction predicts lower lung function at school age in children born very preterm. Arch Dis Child Fetal Neonatal Ed 101(5):F412–F417. https://doi.org/10.1136/ARCHDISCHILD-2015-308922
Pike K, Jane Pillow J, Lucas JS (2012) Long term respiratory consequences of intrauterine growth restriction. Semin Fetal Neonatal Med 17(2):92–98. https://doi.org/10.1016/J.SINY.2012.01.003
Chang DV, Assaf SJ, Tiller CJ, Kisling JA, Tepper RS (2016) Membrane and capillary components of lung diffusion in infants with bronchopulmonary dysplasia. Am J Respir Crit Care Med 193(7):767–771. https://doi.org/10.1164/RCCM.201506-1219OC/SUPPL_FILE/DISCLOSURES.PDF
Duijts L, van Meel ER, Moschino L et al (2020) European Respiratory Society guideline on long-term management of children with bronchopulmonary dysplasia. Eur Respiratory J 55(1). https://doi.org/10.1183/13993003.00788-2019
Um-Bergström P, Pourbazargan M, Brundin B et al (2022) Increased cytotoxic T-cells in the airways of adults with former bronchopulmonary dysplasia. Eur Respiratory J 2102531. https://doi.org/10.1183/13993003.02531-2021
Galderisi A, Calabrese F, Fortarezza F, Abman S, Baraldi E (2019) airway histopathology of adolescent survivors of bronchopulmonary dysplasia. J Pediatr 211:215–218. https://doi.org/10.1016/j.jpeds.2019.04.006
Baraldi E, Bonetto G, Zacchello F, Filippone M (2005) Low exhaled nitric oxide in school-age children with bronchopulmonary dysplasia and airflow limitation. Am J Respir Crit Care Med 171(1):68–72. https://doi.org/10.1164/rccm.200403-298OC
Goulden N, Cousins M, Hart K et al (2021) Inhaled Corticosteroids alone and in combination with long-acting β2 receptor agonists to treat reduced lung function in preterm-born children: a randomized clinical Trial. JAMA Pediatr. https://doi.org/10.1001/JAMAPEDIATRICS.2021.5111
Bonadies L, Moschino L, Baraldi E (2022) Inhaled corticosteroids and long-acting β2 receptor agonists for preterm-born children—new insights but still many questions. JAMA Pediatr. https://doi.org/10.1001/jamapediatrics.2022.0303
Nelin LD, Kielt MJ, Jebbia M, Jadcherla S, Shepherd EG (2022) Bronchodilator responsiveness and dysanapsis in bronchopulmonary dysplasia. ERJ Open Res 8(3). https://doi.org/10.1183/23120541.00682-2021
Levin JC, Annesi CA, Williams DN et al (2022) Discharge practices for infants with bronchopulmonary dysplasia: a survey of national experts. J Pediatr. https://doi.org/10.1016/J.JPEDS.2022.09.018
Berger A, Cramer S, Mader S et al. Respiratory syncytial virus (RSV) in preterm and ill infants. EFCNI Postion Paper. https://www.efcni.org/activities/projects/position-paper-rsv/. Accessed 25 Nov 2022
Brady MT, Byington CL, Davies HD et al (2014) Updated guidance for palivizumab prophylaxis among infants and young children at increased risk of hospitalization for respiratory syncytial virus infection. Pediatrics 134(2):415–420. https://doi.org/10.1542/PEDS.2014-1665
Luna MS, Manzoni P, Paes B et al (2020) Expert consensus on palivizumab use for respiratory syncytial virus in developed countries. Paediatr Respir Rev 33:35–44. https://doi.org/10.1016/j.prrv.2018.12.001
Pamela Griffin M, Yuan Y, Takas T et al (2020) Single-dose nirsevimab for prevention of RSV in preterm infants. N Engl J Med 383(5):415–425. https://doi.org/10.1056/NEJMoa1913556
Griffin MP, Yuan Y, Takas T et al (2020) Single-Dose Nirsevimab for prevention of RSV in preterm infants. N Engl J Med 383(5):415–425. https://doi.org/10.1056/NEJMoa1913556
Domachowske J, Madhi SA, Simões EAF et al (2022) Safety of Nirsevimab for RSV in infants with heart or lung disease or prematurity. N Engl J Med 386(9):892–894. https://doi.org/10.1056/NEJMC2112186
Hofstetter AM, Jacobson EN, Patricia De Hart M, Englund JA (2019) Early childhood vaccination status of preterm infants. Pediatrics 144(3). https://doi.org/10.1542/PEDS.2018-3520
Lee J, Robinson JL, Spady DW (2006) Frequency of apnea, bradycardia, and desaturations following first diphtheria-tetanus-pertussis-inactivated polio-Haemophilus influenzae type B immunization in hospitalized preterm infants. BMC Pediatr 6(1):1–5. https://doi.org/10.1186/1471-2431-6-20/TABLES/2
Saari TN (2003) Immunization of preterm and low birth weight infants. American Academy of Pediatrics Committee on Infectious Diseases. Pediatrics 112(1 Pt 1):193–198. https://doi.org/10.1542/PEDS.112.1.193
Vaccination for preterm infants | The Australian Immunisation Handbook. https://immunisationhandbook.health.gov.au/contents/vaccination-for-special-risk-groups/vaccination-for-preterm-infants. Accessed 4 Nov 2022
Raimondi F, de Winter JP, de Luca D (2020) Lung ultrasound-guided surfactant administration: time for a personalized, physiology-driven therapy. Eur J Pediatr 1–3. https://doi.org/10.1007/s00431-020-03745-x
Loi B, Vigo G, Baraldi E et al (2020) Lung ultrasound to monitor extremely preterm infants and predict BPD:multicenter longitudinal study. Am J Respir Crit Care Med in press(11):1398–1409. https://doi.org/10.1164/rccm.202008-3131OC
Pereda MA, Chavez MA, Hooper-Miele CC et al (2015) Lung ultrasound for the diagnosis of pneumonia in children: a meta-analysis. Pediatrics 135(4):714–722. https://doi.org/10.1542/PEDS.2014-2833
Basile V, di Mauro A, Scalini E et al (2015) Lung ultrasound: a useful tool in diagnosis and management of bronchiolitis. BMC Pediatr 15(1):1–8. https://doi.org/10.1186/S12887-015-0380-1/TABLES/6
Katz SL, Luu TM, Nuyt AM et al (2017) Long-term follow-up of cardiorespiratory outcomes in children born extremely preterm: recommendations from a Canadian consensus workshop. Paediatr Child Health 22(2):75–79. https://doi.org/10.1093/PCH/PXX028
Everitt LH, Awoseyila A, Bhatt JM, Johnson MJ, Vollmer B, Evans HJ (2021) Weaning oxygen in infants with bronchopulmonary dysplasia. Paediatr Respir Rev 39:82–89. https://doi.org/10.1016/J.PRRV.2020.10.005
Ferrante G, Simoni M, Cibella F et al (2013) Third-hand smoke exposure and health hazards in children. Monaldi Arch Chest Dis 79(1):38–43. https://doi.org/10.4081/MONALDI.2013.108
Gastaldi A, Donà D, Barbieri E, Giaquinto C, Bont LJ, Baraldi E (2021) COVID-19 lesson for respiratory syncytial virus (RSV): hygiene works. Children 8(12):1144. https://doi.org/10.3390/CHILDREN8121144
Lista G, Meneghin F, Bresesti I, Cavigioli F (2017) Nutritional problems of children with bronchopulmonary dysplasia after hospital discharge. Pediatr Med Chir 39(4):120–123. https://doi.org/10.4081/PMC.2017.183
Crump C, Sundquist J, Winkleby MA, Sundquist K (2019) Gestational age at birth and mortality from infancy into mid-adulthood: a national cohort study. Lancet Child Adolesc Health 3(6):408–417. https://doi.org/10.1016/S2352-4642(19)30108-7
European Standards of Care for Newborn Health – EFCNI. https://www.efcni.org/activities/projects/escnh/. Accessed 21 Oct 2022
Choi EK, Shin SH, Kim EK, Kim HS (2019) Developmental outcomes of preterm infants with bronchopulmonary dysplasia-associated pulmonary hypertension at 18–24 months of corrected age 11 Medical and Health Sciences 1114 Paediatrics and Reproductive Medicine. BMC Pediatr 19(1):1–8. https://doi.org/10.1186/S12887-019-1400-3/TABLES/4
Lee JM, Choi YH, Hong J et al (2019) Bronchopulmonary dysplasia is associated with altered brain volumes and white matter microstructure in preterm infants. Neonatology 116(2):163–170. https://doi.org/10.1159/000499487
Ibrahim J, Mir I, Chalak L (2018) Brain imaging in preterm infants <32 weeks gestation: a clinical review and algorithm for the use of cranial ultrasound and qualitative brain MRI. Pediatr Res 84(6):799–806. https://doi.org/10.1038/s41390-018-0194-6
Sacchi C, O’Muircheartaigh J, Batalle D et al (2021) neurodevelopmental outcomes following intrauterine growth restriction and very preterm birth. J Pediatr 238:135-144.e10. https://doi.org/10.1016/j.jpeds.2021.07.002
Johnson S, Marlow N (2011) Preterm birth and childhood psychiatric disorders. Pediatr Res 69(8):11–18. https://doi.org/10.1203/pdr.0b013e318212faa0
Vanes LD, Murray RM, Nosarti C (2022) Adult outcome of preterm birth: implications for neurodevelopmental theories of psychosis. Schizophr Res 247:41–54. https://doi.org/10.1016/J.SCHRES.2021.04.007
Humphreys P, Deonandan R, Whiting S et al (2007) Factors associated with epilepsy in children with periventricular leukomalacia. J Child Neurol 22(5):598–605. https://doi.org/10.1177/0883073807302599
Wang LJ, Hu Y, Wang W, Zhang CY, Bai YZ, Zhang SC (2020) Gastroesophageal reflux poses a potential risk for late complications of bronchopulmonary dysplasia: a prospective cohort study. Chest 158(4):1596–1605. https://doi.org/10.1016/J.CHEST.2020.05.523
Bauer SE, Vanderpool CPB, Ren C, Cristea AI (2021) Nutrition and growth in infants with established bronchopulmonary dysplasia. Pediatr Pulmonol 56(11):3557–3562. https://doi.org/10.1002/PPUL.25638
Young L, Morgan J, McCormick FM, McGuire W (2012) Nutrient-enriched formula versus standard term formula for preterm infants following hospital discharge. Cochrane Database Syst Rev (3). https://doi.org/10.1002/14651858.CD004696.PUB4
Rocha G, Guimarães H, Pereira-Da-silva L (2021) The role of nutrition in the prevention and management of bronchopulmonary dysplasia: a literature review and clinical approach. Int J Environ Res Public Health 18(12). https://doi.org/10.3390/IJERPH18126245
Ge H, Qiao Y, Ge J et al (2022) Effects of early vitamin D supplementation on the prevention of bronchopulmonary dysplasia in preterm infants. Pediatr Pulmonol 57(4):1015–1021. https://doi.org/10.1002/PPUL.25813
Agostoni C, Buonocore G, Carnielli VP et al (2010) Enteral nutrient supply for preterm infants: commentary from the European Society of Paediatric Gastroenterology, Hepatology and Nutrition Committee on Nutrition. J Pediatr Gastroenterol Nutr 50(1):85–91. https://doi.org/10.1097/MPG.0B013E3181ADAEE0
Kumar M, Chowdhury R, Sinha B et al (2022) Enteral calcium or phosphorus supplementation in preterm or low birth weight infants: a systematic review and meta-analysis. Pediatrics 150(Suppl 1). https://doi.org/10.1542/PEDS.2022-057092M
Ehrenkranz RA (2014) Extrauterine growth restriction: is it preventable? J Pediatr (Rio J) 90(1):1–3. https://doi.org/10.1016/J.JPED.2013.10.003
Pierrat V, Marchand-Martin L, Guemas I et al (2011) Height at 2 and 5 years of age in children born very preterm: the EPIPAGE study. Arch Dis Child Fetal Neonatal Ed 96(5). https://doi.org/10.1136/ADC.2010.185470
Euser AM, de Wit CC, Finken MJJ, Rijken M, Wit JM (2008) Growth of preterm born children. Horm Res 70(6):319–328. https://doi.org/10.1159/000161862
Baraldi E, Galderisi A (2021) Noncommunicable diseases of prematurity: time for a new mindset? J Pediatr. https://doi.org/10.1016/j.jpeds.2021.06.064
Crump C, Howell EA, Stroustrup A, McLaughlin MA, Sundquist J, Sundquist K (2019) Association of preterm birth with risk of ischemic heart disease in adulthood. JAMA Pediatr 173(8):736–743. https://doi.org/10.1001/jamapediatrics.2019.1327
Sutherland MR, Bertagnolli M, Lukaszewski MA et al (2014) Preterm birth and hypertension risk: The oxidative stress paradigm. Hypertension 63(1):12–18. https://doi.org/10.1161/HYPERTENSIONAHA.113.01276
Markopoulou P, Papanikolaou E, Analytis A, Zoumakis E, Siahanidou T (2019) Preterm birth as a risk factor for metabolic syndrome and cardiovascular disease in adult life: a systematic review and meta-analysis. J Pediatr 210:69-80.e5. https://doi.org/10.1016/j.jpeds.2019.02.041
Menendez-Castro C, Rascher W, Hartner A (2018) Intrauterine growth restriction - impact on cardiovascular diseases later in life. Mol Cell Pediatr 5(1). https://doi.org/10.1186/S40348-018-0082-5
Kopec G, Shekhawat PS, Mhanna MJ (2017) Prevalence of diabetes and obesity in association with prematurity and growth restriction. Diabetes Metab Syndr Obes 10:285. https://doi.org/10.2147/DMSO.S115890
Crump C, Sundquist J, Winkleby MA, Sundquist K (2019) Preterm birth and risk of chronic kidney disease from childhood into mid-adulthood: National cohort study. The BMJ 365. https://doi.org/10.1136/bmj.l1346
Physical activity. https://www.who.int/news-room/fact-sheets/detail/physical-activity. Accessed 19 Oct 2022
Morales Mestre N, Papaleo A, Morales Hidalgo V, Caty G, Reychler G (2018) Physical activity program improves functional exercise capacity and flexibility in extremely preterm children with bronchopulmonary dysplasia aged 4–6 years: a randomized controlled trial. Arch Bronconeumol 54(12):607–613. https://doi.org/10.1016/J.ARBRES.2018.05.001
Hillier E, Hawkins S, Friedrich MG, Nuyt AM (2019) The assessment of functional cardiovascular health after exercise intervention in young adults born preterm. Eur Heart J Cardiovasc Imaging 20(Supplement_2). https://doi.org/10.1093/EHJCI/JEZ122.003
Frezza S, Catenazzi P, Gallus R et al (2019) Hearing loss in very preterm infants: should we wait or treat? Acta Otorhinolaryngol Ital 39(4):257. https://doi.org/10.14639/0392-100X-2116
Leung MPS, Thompson B, Black J, Dai S, Alsweiler JM (2018) The effects of preterm birth on visual development. Clin Exp Optom 101(1):4–12. https://doi.org/10.1111/CXO.12578
Misund AR, Nerdrum P, Diseth TH (2014) Mental health in women experiencing preterm birth. BMC Pregnancy Childbirth 14(1):1–8. https://doi.org/10.1186/1471-2393-14-263/TABLES/5
Thanh NX, Toye J, Savu A, Kumar M, Kaul P (2015) Health service use and costs associated with low birth weight–a population level analysis. J Pediatr 167(3):551-556.e3. https://doi.org/10.1016/J.JPEDS.2015.06.007
Russell RB, Green NS, Steiner CA et al (2007) Cost of hospitalization for preterm and low birth weight infants in the United States. Pediatrics 120(1). https://doi.org/10.1542/PEDS.2006-2386
Cavallo MC, Gugiatti A, Fattore G, Gerzeli S, Barbieri D, Zanini R (2015) Cost of care and social consequences of very low birth weight infants without premature- related morbidities in Italy. Ital J Pediatr 41(1):1–12. https://doi.org/10.1186/S13052-015-0165-Z/FIGURES/2
Lapcharoensap W, Bennett MV., Xu X, Lee HC, Dukhovny D (2019) Hospitalization costs associated with bronchopulmonary dysplasia in the first year of life. J Perinatol 40(1):130–137. https://doi.org/10.1038/s41372-019-0548-x
Petrou S, Sach T, Davidson L (2001) The long-term costs of preterm birth and low birth weight: results of a systematic review. Child Care Health Dev 27(2):97–115. https://doi.org/10.1046/J.1365-2214.2001.00203.X
Lapcharoensap W, Lee HC, Nyberg A, Dukhovny D (2018) Health Care and societal costs of bronchopulmonary dysplasia. NeoReviews 19(4):e211. https://doi.org/10.1542/NEO.19-4-E211
Funding
Open access funding provided by Università degli Studi di Padova within the CRUI-CARE Agreement.
Author information
Authors and Affiliations
Contributions
Luca Bonadies and Maria Elena Cavicchiolo equally contributed in performing the literature search, drafting the paper and in its revisions. Laura Moschino and Elena Priante contributed in drafting and revising the paper. Eugenio Baraldi conceived the idea and supervised the paper writing and revised it critically for important intellectual content. All authors read and approved the final version of the manuscript.
Corresponding author
Ethics declarations
Ethical approval
This is a review work, consequently ethical approval is not required.
Conflict of interest
The authors declare no competing interests.
Additional information
Communicated by Daniele De Luca.
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Bonadies, L., Cavicchiolo, M.E., Priante, E. et al. Prematurity and BPD: what general pediatricians should know. Eur J Pediatr 182, 1505–1516 (2023). https://doi.org/10.1007/s00431-022-04797-x
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00431-022-04797-x